A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease

Elaheh Vahabnezhad, Shervin Rabizadeh, Marla C. Dubinsky

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Despite increasing use of infliximab (IFX) in children with Crohn's disease (CD) and ulcerative colitis (UC), long-term durability and safety of IFX beyond 1 year is limited in pediatric inflammatory bowel disease. Methods: We performed a 10-year single-center retrospective cohort study of 188 patients initiating IFX at

Original languageEnglish (US)
Pages (from-to)606-613
Number of pages8
JournalInflammatory Bowel Diseases
Volume20
Issue number4
DOIs
StatePublished - 2014
Externally publishedYes

Keywords

  • Anti-infliximab antibody
  • Crohn's disease
  • Inflammatory bowel disease
  • Infliximab
  • Pediatric
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy
  • Medicine(all)

Fingerprint Dive into the research topics of 'A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this